Second Genome Appoints Joseph Dal Porto, Ph.D., as Chief Scientific Officer

January 19, 2022, BRISBANE, Calif.

Read More

Second Genome Granted U.S. Patent for Proteins for the Treatment or Prevention of Epithelial Barrier Function Disorders

December 20, 2021, BRISBANE, Calif

Read More

Second Genome Presents Preclinical Data at Crohn’s & Colitis Foundation’s® IBD Innovate Conference for Potential First in Class Mucosal Healing Therapeutic SG-5-00455

November 18, 2021, BRISBANE, Calif.

Read More

Second Genome Presents Preclinical Data at SITC 2021 Demonstrating that a CXCR3-Positive Allosteric Modulator, SG-3-00802, Targets a Key Mechanism Required for Efficacious Immunotherapy

November 12, 2021, BRISBANE, Calif.

Read More

Second Genome Presents Preclinical Data Highlighting Potential Therapeutic Implications of Altered Gut Microbiome and Metabolites in Autism Spectrum Disorder Model and Parkinson’s Disease at The Society for Neuroscience Annual Meeting

November 11, 2021, BRISBANE, Calif.

Read More

Second Genome Presents Preclinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Demonstrating that a Novel Peptide, SG-3-0020, Upregulates Co-stimulatory and Checkpoint Pathways

October 7, 2021, BRISBANE, Calif.

Read More

Second Genome Announces Research Collaboration with Virginia Commonwealth University to Identify a Non-Invasive NASH Composite Biomarker

September 23, 2021, BRISBANE, Calif.

Read More

Second Genome Presents Preclinical Data at ESMO 2021 Demonstrating that a Novel Microbiome-Derived Peptide, SG-3-00802, Reverses Resistance to Anti-Programmed Death Protein-1 (PD-1) Therapy

September 16, 2021, BRISBANE, Calif.

Read More